MedTrace Logo

PelvEx 4: Advanced Pelvic Malignancy and the Role of the Multi-disciplinary Team Meeting

NCT05076305 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2021-10-13

No results posted yet for this study

Summary

The treatment of locally advanced and recurrent rectal cancers is highly individualized to each patient and their pattern of disease, and this decision is often made at the Multidisciplinary Team (MDT) meeting . The PelvEx collaborative was designed with the intent to provide greater international consensus on appropriate treatment decisions for this cohort. However, we propose that international variation exists in how certain patients will be evaluated, assessed and ultimately treated despite having the same disease. We plan to measure this variation in order to provide a greater understanding of the differences that exist.

Conditions

  • Multidisciplinary Communication
  • Locally Advanced Rectal Cancer
  • Recurrent Rectal Cancer
  • Multidisciplinary Team Meeting (MDT)
  • Treatment Decisions

Interventions

OTHER

No specific intervention; cases are retrospective and patients have already been treated.

To assess the geographic variation that exists in the management of locally advanced and recurrent rectal cancers.

Sponsors & Collaborators

  • PelvEx collaborative

    collaborator UNKNOWN

  • St Vincent's University Hospital, Ireland

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-15
Primary Completion
2021-12-01
Completion
2022-02-01

Countries

  • Ireland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05076305 on ClinicalTrials.gov